While MEK inhibitors have shown success in the treatment of BRAF-mutant melanoma, they have shown limited efficacy in RAS-mutant human tumor cell lines [86] and RAS-driven mouse models of cancer [87]. Here, MAP2K7 is linked to neoplasm.